XTalks
AUGUST 30, 2022
One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.
The Pharma Data
JANUARY 3, 2021
The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. . +46 7686 650 11. 1 Good Manufacturing Practice. 2 Proof of Concept. 3 Active Pharmaceutical Ingredient. Finnish time. About Nanoform. Nanoform is an innovative nanoparticle medicine enabling company.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
NOVEMBER 26, 2020
The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. For investor relations queries, please contact: Henri von Haartman , Director of Investor Relations hvh@nanoform.com / +46 7686 650 11. Finnish time. About Nanoform.
The Pharma Data
JANUARY 27, 2021
Each study is planned to be carried out over an approximately two-week period as an open label, randomized, crossover, two-period, two-sequence, single dose pilot study to assess the relative bioavailability of each product. About XPhyto Therapeutics Corp. XPhyto Therapeutics Corp.
Pharmaceutical Technology
FEBRUARY 3, 2023
In 2021, 72% of newly approved drugs were small molecules, and almost 50% of new drugs approved were OSD. While the industry is seeing advances in alternative drug delivery systems, oral solid doses, such as pills, capsules and soft gels, remain at the forefront of the industry.
Expert insights. Personalized for you.
83 
Let's personalize your content